Indivior Pharmaceuticals, Inc. (INDV)

Over the past six months, Indivior's stock price has been impacted by several events. The company reported strong first-quarter 2026 results, raising its full-year financial guidance, which contributed to a significant increase in the stock price. Indivior completed its redomiciliation to the U.S. in January 2026. In February 2026, Indivior initiated a share repurchase program of up to $400 million and completed a $500 million convertible senior notes offering in April 2026. Indivior announced the cessation of internal development for two OUD drug candidates in April 2026. In November 2025, the company concluded a legacy Department of Justice matter with a $295 million payment.

The provided information does not explicitly indicate any significant demand seasonality for Indivior Pharmaceuticals, Inc.'s products and services. The company's focus on chronic conditions like opioid use disorder suggests a more consistent demand profile rather than seasonal fluctuations.

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for substance use disorders, especially opioid use disorder. Its core mission is to provide evidence-based treatment and advance the understanding of OUD as a chronic, yet treatable, brain disease. Key medications include SUBLOCADE, a monthly injectable for moderate to severe OUD; SUBOXONE Film for OUD, facing generic competition; PERSERIS, a once-monthly extended-release injection for schizophrenia; OPVEE for opioid overdose reversal; and SUBOXONE and SUBUTEX Tablets for OUD treatment. In January 2026, Indivior completed its redomiciliation from the United Kingdom to the United States.

Indivior Pharmaceuticals generates the vast majority of its revenue in the United States, with additional contributions from the United Kingdom and the rest of the world. The company maintains offices and research centers in Virginia and North Carolina in the U.S., and in the UK. Its product portfolio is available in over 30 countries globally.

In the past year, Indivior has focused on advancing evidence-based treatment for opioid use disorder and combating the opioid crisis. The company released a cost impact model suggesting that SUBLOCADE can reduce staff time and costs in correctional facilities. Indivior also presented new real-world data at the ASAM 2026 Annual Conference, supporting remission as a treatment outcome and reinforcing the clinical benefits of monthly injectable buprenorphine for OUD. There have been no new major events that have negatively impacted Indivior's brand reputation in the past year.

Indivior Pharmaceuticals Inc. is predominantly owned by institutional shareholders, who hold 99.63% of the stock. Insiders own 0.76%, while retail investors hold 0.00%. Major institutional owners include BlackRock, Inc., Oaktree Capital Management LP, and Fuller Thaler Asset Management Inc., along with Vanguard Group Inc., State Street Corp., Morgan Stanley, Deerfield Management Company, L.P., Goldman Sachs Group Inc., and Acadian Asset Management Llc.